trending Market Intelligence /marketintelligence/en/news-insights/trending/tt5uEMlk8jpmQ_tGgz3tDg2 content esgSubNav
In This List

Consun Pharmaceutical considering spin off of traditional medicines unit

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Consun Pharmaceutical considering spin off of traditional medicines unit

Consun Pharmaceutical Group Ltd. is considering a potential spin off and listing of its indirect, non-wholly owned unit Guangxi Yulin Pharmaceutical Group Co. Ltd. and its subsidiaries.

Yulin Pharmaceutical develops and sells traditional Chinese and natural medicines. It has not yet submitted any listing application to the China Securities Regulatory Commission, the relevant stock exchange in China, or the Hong Kong Stock Exchange, Consun said in a release.

A financial adviser for the potential spin off and listing was appointed by Consun Pharmaceutical on Oct. 18, it said.